𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies

✍ Scribed by Paul K. Paik; Charles M. Rudin; Andrew Brown; Naiyer A. Rizvi; Naoko Takebe; William Travis; Leonard James; Michelle S. Ginsberg; Rosalyn Juergens; Susan Markus; Leslie Tyson; Sara Subzwari; Mark G. Kris; Lee M. Krug

Publisher
Springer
Year
2010
Tongue
English
Weight
273 KB
Volume
66
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase I study of sequential administra
A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors
✍ Caio M. S. Rocha Lima; Carlo V. Catapano; Daniel Pacheco; Carol A. Sherman; Greg πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 114 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Based on preclinical findings and on the clinical antitumor efficacy of sequential paclitaxel/topotecan and topotecan/etoposide, the authors sought to define the maximum tolerated doses (MTDs) and dose‐limiting toxicities (DLTs) associated with a sequential combination of

A phase-I clinical study of autologous t
A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer
✍ Hendrik Veelken; Andreas Mackensen; Michael Lahn; Gabriele KΓΆhler; Daniel Becker πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 French βš– 257 KB πŸ‘ 2 views

Tumor cells transfected to express immunostimulatory cytokines, or admixed with similarly modified bystander cells, are able to induce immune responses against unmodified tumor cells in animal models. For treatment of human patients, a vaccine composed of autologous tumor cells and IL-2-secreting al